Previous 10 | Next 10 |
July 18, 2019 Palm Beach, FL –July 18, 2019 – Acute myeloid leukemia (AML) is a cancer that is rarely seen before age 45 with the average age of onset around 65. It is the most common of the four major types of leukemia. Without treatment, AML is often deadly wi...
HOUSTON , July 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced additional positive interim safety and effic...
Vislink Technologies (NASDAQ: VISL ) +265% on $2.8M contract . More news on: Vislink Technologies, Inc., Valeritas Holdings, Inc., Harmonic Inc., Stocks on the move, Read more ...
Moleculin Biotech (NASDAQ: MBRX ) has filed new patents covering the production and reconstitution of Annamycin, for the treatment of relapsed or refractory acute myeloid leukemia (AML). More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, Read more ... ...
July 10, 2019 Palm Beach, FL –July 10, 2019 – The American Cancer Society estimates that in 2019 there will be about 61,780 new cases of leukemia and 22,840 deaths from leukemia and 21,450 new cases of acute myeloid leukemia (AML). Most will be in adults. About 1...
HOUSTON , July 10, 2019 /PRNewswire/ -- Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has filed new patents covering the pr...
Moleculin Biotech (NASDAQ: MBRX ) is up 10% postmarket after filing a presentation it says it will use in meetings with the investment community. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Soliton ( SOLY ) had a recent Reg A+ IPO in February 2019, with an unproven device that is supposed to assist a laser with tattoo and cellulite removal. SOLY is a relentless PR machine that we believe will end very badly for shareholders who think they are holding a solid investment. The compa...
Moleculin Biotech (NASDAQ: MBRX ): Q1 GAAP EPS of -$0.14 misses by $0.05 . More news on: Moleculin Biotech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOUSTON , May 14, 2019 /PRNewswire/ -- Moleculin Biotech, Inc. (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the firs...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...